Articles

Use of the prevented fraction for the population to determine deaths averted by existing prevalence of physical activity: a descriptive study

Tessa Strain, Søren Brage, Stephen J Sharp, Justin Richards, Marko Tainio, Ding Ding, Jacques Benichou, Paul Kelly

Summary

Background Disease and mortality burdens of unhealthy lifestyle behaviours are often reported. In contrast, the positive narrative around the burdens that an existing behaviour have averted is rarely acknowledged. We aimed to estimate the prevented fraction for the population (PFP) for premature mortality averted by physical activity on a global scale.

Methods In this descriptive study, we obtained previously published data on physical activity prevalence (2001–16) and relative risks of all-cause mortality for 168 countries. We combined the data in Monte-Carlo simulations to estimate country-specific, mean PFP values, corresponding to percentage of mortality averted, and their 95% CIs. High prevented fractions indicated an increased proportion of deaths averted due to physical activity. Using mortality data for all people in a country aged 40–74 years, we estimated the number of premature deaths averted for all adults and by gender. We present the median and range of the prevented fractions globally, by WHO region, and by World Bank income classification.

Findings The global median PFP was $15 \cdot 0\%$ (range $6 \cdot 6-20 \cdot 5$), conservatively equating to $3 \cdot 9$ million (95% CI $2 \cdot 5-5 \cdot 6$) premature deaths averted annually. The African region had the highest median prevented fraction ($16 \cdot 6\%$ [range $12 \cdot 1-20 \cdot 5$]) and the Americas had the lowest ($13 \cdot 1\%$ [$10 \cdot 8-16 \cdot 6$]). Low-income countries tended to have higher prevented fractions (group median $17 \cdot 9\%$ [$12 \cdot 3-20 \cdot 5$]) than high-income countries ($14 \cdot 1\%$ [$6 \cdot 6-17 \cdot 8$]). Globally, the median prevented fraction was higher for men ($16 \cdot 0\%$ [$7 \cdot 8-20 \cdot 7$] than women ($14 \cdot 1\%$ [$5 \cdot 0-20 \cdot 4$]).

Interpretation Existing physical activity prevalence has contributed to averting premature mortality across all countries. PFP has utility as an advocacy tool to promote healthy lifestyle behaviours. By making the case of what has been achieved, the prevented fraction can show the value of current investment and services, which might be conducive to political support.

Funding UK Medical Research Council, British Heart Foundation, Cancer Research UK, Economic and Social Research Council, National Institute for Health Research, Wellcome Trust, Heart Foundation Australia.

Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.

Introduction

When making the case for the promotion of healthy lifestyle behaviours, statistics that quantify the burden of reciprocal unhealthy behaviours are often cited.¹⁻³ For example, physical inactivity is responsible for 6.4% of global premature mortality, insufficient fruit and vegetable consumption for 11.3%, and harmful alcohol consumption for 5.3%;³⁻⁵ although methodological differences can lead to substantially different results.⁶⁷ Some researchers advocate that stressing the harms of unhealthy behaviours can strengthen the case in promoting healthy lifestyles.⁸ We suggest that an alternative strategy is to present the complementary positive, gain-framed message that clarifies to what extent existing healthy behaviours have already reduced burdens of disease and mortality.⁹

In this Article, we describe and explore the use of the prevented fraction for the population (PFP), defined as the proportion of a disease outcome or mortality that has been averted or prevented due to the presence of a protective factor (panel).10 This is not a new concept: it was first proposed by Miettinen¹² in 1974, and is included in the International Epidemiological Association's A Dictionary of Epidemiology,10 and the Encyclopedia of Epidemiologic Methods of the Wiley Reference Series in Biostatistics.13 PFP is a concept closely related to population attributable fraction (PAF), defined as the proportion of disease cases or mortality cases attributable to a harmful risk factor¹⁰ (in other words, the proportion that could be averted or prevented if a harmful risk factor was eliminated). The appendix (pp 1-2) presents graphical depictions of the two concepts. PAF would provide an aspirational indicator of what could be achieved if all members of the public adopted a healthy behaviour. Under most circumstances, such widespread adoption would need new investment and resources. Conversely, PFP can be used as a positive





Lancet Glob Health 2020; 8: e920–30

See **Comment** page e867

Medical Research Council Epidemiology Unit, University of Cambridge, Cambridge, UK (T Strain PhD, S Brage PhD, S I Sharp MSc. M Tainio PhD): Physical Activity for Health Research Centre, Institute of Sport, Physical Education, and Health Sciences, Morav House School of Education and Sport, University of Edinburgh, Edinburgh, UK (T Strain, P Kelly PhD); Prevention Research Collaboration, Sydney School of Public Health, Faculty of Medicine and Health and Charles Perkins Centre. The University of Sydney, Camperdown, NSW, Australia (J Richards PhD, D Ding PhD); Health Services Research Centre. Faculty of Health, Victoria University of Wellington. Wellington, New Zealand (J Richards); Sustainable Urbanisation Programme. Finnish Environment Institute. Helsinki, Finland (M Tainio); Systems Research Institute, Polish Academy of Sciences, Warsaw, Poland (M Tainio); Department of Biostatistics and Clinical Research, Rouen University Hospital, Rouen, France (Prof J Benichou PhD); and the French National Institute of Health and Medical Research, Unit 1018, University of Rouen, Rouen, France (Prof J Benichou)

Correspondence to: Dr Tessa Strain, Medical Research Council Epidemiology Unit, University of Cambridge, Cambridge CB2 0QQ, UK tessa.strain@mrc-epid.cam. ac.uk

See Online for appendix

Research in context

Evidence before this study

The case for promoting healthy lifestyle behaviours is often framed negatively in terms of the harm (disease and death) that can be attributed to the absence of healthy behaviours or presence of unhealthy behaviours. In an initial literature search we aimed to identify examples of use of prevented fraction for the population (PFP) relating to lifestyle behaviours, such as physical activity, diet and nutrition, alcohol, and smoking. Because of the variety of terms used for the concept, we searched PubMed and WebofScience for the terms "prevented fraction", "preventive fraction" and "preventable fraction". We searched for papers published from database inception until June 12, 2019, without language restrictions. Compared with the thousands of studies on disease or mortality burden, we identified only 12 published studies that used a version of PFP to estimate the proportion of a disease or mortality burden that is already being averted or prevented by existing prevalence of a healthy behaviour. However, no studies had estimated prevented fraction at a global level for total physical activity behaviour, nor had the recommended formula for addressing confounding been used.

Added value of this study

To the best of our knowledge, this study is the first to quantify the effect that existing total physical activity prevalence has

indicator of accomplishment, in terms of how much good is being done or has been done by the amount of existing beneficial behaviours within a population. As such, PFP could be a powerful advocacy tool among policy makers, by promoting positive thinking around healthy lifestyle behaviours (ie, "look how much benefit this behaviour is already providing; let's create more benefit by increasing prevalence of the behaviour further"). Although this approach has the risk of causing complacency (ie, "the behaviour is already providing benefit, why invest in more?"), it could also be a lever to protect and maintain services. As such, this could be a potentially powerful approach with realistic targets in challenging economic climates.

The few studies that have used PFP are not easy to trace because of inconsistency in terminology. The terms preventive fraction and preventable fraction are variously used. We searched the literature for the three different terms and found the concept in question has been used primarily in oral health, vaccine, and genetic research (appendix pp 3–7). We found 12 examples of use that quantified the proportion of disease burden or mortality burden that had been averted or could have been averted due to a current exposure, in relation to lifestyle behaviours or their physiological markers. Specifically, these studies quantified averted disease or mortality burden due to cycling or walking behaviour or fitness, fruit and vegetable or vitamin consumption, aspirin had on averting premature mortality at the global, regional, and country levels. We showed that during 2001–16 across 168 countries, the median PFP for premature mortality averted by existing physical activity prevalence was 15·0%, conservatively equating to 3.9 million deaths averted annually. We also provided information at a regional level: Africa had the highest median PFP, indicating the greatest percentage of premature mortality averted by physical activity. The Americas had the lowest prevented fraction, closely followed by the Eastern Mediterranean region. We further identified a tendency towards increased prevented fractions in lower income countries compared with higher income countries, and in men compared with women.

Implications of all the available evidence

PFP makes the complementary positive case for physical activity promotion, focusing on the benefits currently accomplished rather than the harms from insufficient compliance to recommended levels. This might be a powerful advocacy tool in terms of persuading policy makers and wider societies that physical activity behaviour has quantifiable value, and that existing prevalence should be at least preserved.

intake, use of oral contraceptives, sunscreen use, preventive measures for problem drinking, and interventions to prevent fractures. All of these studies determined PFP with formula 2, presented in the panel. Formula 2 is appropriate for scenarios with no confounding factors affecting the relationship between exposure prevalence and the risk of the disease outcome.¹⁴ As the absence of confounding is a rarity in the study of lifestyle behaviours, formula 3 (panel) is preferable, which addresses the potential sources of confounding.¹¹ To the best of our knowledge, such an approach has not been applied before to global physical activity prevalence.

In this study, we present the first global application of PFP, using formula 3, to obtain estimates of the proportion and number of premature deaths averted by the existing prevalence of physical activity. We obtained results for 168 countries with two counterfactual scenarios for comparison: no activity in the population, and a plausible minimum physical activity prevalence.

Methods

Study design and formulae application

We did a descriptive study to estimate PFP from the existing prevalence of physical activity for all-cause mortality in 168 countries, using the formula that addresses potential confounding factors (formula 3; panel). The study protocol including all modifications is provided in the appendix (pp 10–11).

We defined physical activity as meeting the WHO global recommendation of at least 150 min of moderateintensity aerobic activity, or 75 min of vigorous-intensity activity, or an equivalent combination, throughout one week.¹⁵ We used population-level, age-standardised and harmonised prevalence data on physical activity for the years 2001–16 for 168 countries, published by Guthold and colleagues,¹⁶ to estimate the prevalence of physical activity among people who died (P_d), with the formula:

 $P_{d} = (P_{e} \times RR) / [(P_{e} \times RR) + (1-P_{e})]$

In this formula (denoted formula 4; appendix p 9), P_e is the prevalence of activity in the population¹⁶ and RR is the unadjusted relative risk of premature all-cause mortality for active individuals of the population, compared with inactive individuals. The unadjusted RR was taken from a meta-analysis on the association between physical inactivity and all-cause mortality by Lee and colleagues.¹⁷ We estimated 95% CIs for P_d using the 95% CIs for P_e in this formula.

We used the P_a estimates and adjusted RR, also estimated by Lee and colleagues, ^{*v*} in formula 3 to estimate PFP for each country. To estimate the error conservatively, we generated distributions for P_a and adjusted RR that reflected their 95% CIs. We used a binomial distribution for P_a and a normal distribution for the natural log of RR.

Subsequently, we did 10 000 Monte-Carlo simulations, in which each simulation selected one value from the generated P_a and RR distributions, and used them in formula 2 (panel). We considered the 10 000 estimates produced by the simulations to represent the probability distribution of the true PFP. We present the mean of these simulated values, with the 95% CIs represented by the 2.5th and 97.5th percentiles of the distribution. The appendix presents a graphical overview of the method (p 12), and the parameters for generated prevalence distributions of RR and P_a (pp 13–21).

Mortality averted estimation

To convert PFP into an estimate of number of premature deaths averted, we obtained the country-specific number of all-cause deaths between the ages of 40-74 years from the mortality datasets of the UN World Population Prospects tool. We chose this age range to reflect the ages at which premature mortality could most plausibly be caused by inactivity. We selected mortality data from July 1, 2010, to June 30, 2015, which is within the period represented by prevalence data, and divided by 5 to estimate annual figures. By dividing the observed number of deaths by 1 minus the prevented fraction, we obtained estimates for the hypothetical total number of deaths that would have been observed had there been no activity in the population in each nation (ie, a zero counterfactual). The total number of premature deaths averted was the difference between the observed and

Panel: Prevented fraction for the population (PFP)

PFP for a given outcome is defined by the formula:

incidence rate in the unexposed

In this equation (denoted formula 1), the exposure is protective.¹⁰ PFP can also be expressed in terms of the prevalence of exposure (P_e) and the relative risk (RR) for exposure relative to non-exposure¹¹ (formula 2; appendix p 8): PFP=P_e (1–RR)

If potential confounders are present that affect both the prevalence of exposure and the risk of disease or mortality, the following formula (denoted formula 3; appendix p 9) is recommended,¹¹ where P_d is the prevalence of exposure among disease cases or deceased cases:

$$PFP = \frac{P_d(1-RR)}{[1-(1-RR)(1-P_d)]}$$

The proportion estimated by each of these formulae can be interpreted as the reduction in the burden of disease or mortality that has occurred due to existing exposure levels, compared with if the whole population was unexposed.


For example, in the present study of physical activity and premature mortality, we estimated the global median PFP to be 15.0% (range 6.6-20.5). This means that, due to existing physical activity levels, the burden of premature mortality is 15% lower than it would have been if the whole population was inactive.

The hypothetical denominator is analogous to a situation in which an individual buys a discounted item. The individual might pay ± 0.80 for an item (analogous to the observed number of deaths), and be told that they have saved ± 0.20 (analogous to the estimated number of cases that have been averted). The original ± 1.00 cost of the item was never experienced (ie, the hypothetical total number of deaths), but it is the correct denominator of the fraction to calculate the percentage saved (20%).

hypothetical totals. A 95% CI range for the estimate of deaths averted was calculated with the lower and upper 95% CIs of the prevented fraction.

In addition to presenting the country-level estimates, we summarised the results by WHO region, and by 2019 World Bank income classification;¹⁸ each of these groupings were further subdivided into gender-specific results according to the UN mortality datasets. Countries without an income categorisation (Cook Islands, Niue, occupied Palestinian territory, and Tokelau) were classified according to similar neighbouring economies. As these groups of countries were small (often <20) and the estimates did not typically follow a normal distribution, we present group-level medians and ranges to summarise the data; summary values representative of all 168 countries are presented in the same way for comparability.

For 14 nations we were unable to obtain mortality data; these made up less than 0.01% of the world's population (appendix p 22). For these countries, we imputed mortality data at ages 40–74 years on the basis of the median ratio of deaths to the total population in countries in the same WHO region and World Bank income For the UN World Population Prospects tool see https://population.un.org/wpp/



(Figure continues on next page)

categories; these median ratios were multiplied by the population of the country without mortality data.

Sensitivity analysis

We did three sensitivity analyses. The first two used formula 2: with the unadjusted RR to provide unadjusted results, and with the adjusted RR as this was the method most commonly used in the literature to date (appendix pp 4-7). In the third analysis we used a plausible minimum physical activity prevalence counterfactual. This comparison attempted to focus on the burden averted due to modifiable physical activity prevalence, not including the residual levels (ie, individuals who would be active regardless of initiatives to promote activity). For this comparison, we used the median of the lowest observed prevalence of activity from each region. We opted for this measure rather than the observed lowest prevalence from a single nation because environmental and cultural factors vary widely between regions and might influence activity levels. Using formula 4, we obtained a P_{d} for this minimum prevalence of activity. We adapted formula 3 to allow for a non-zero counterfactual, analogous to the population impact fraction formulae often used for PAF (denoted formula 5; appendix pp 23-25).¹¹ Countries with a prevalence of activity lower than the chosen counterfactual value were

excluded from this analysis. All analyses were done in STATA (version 15.1), and forest plots of the data were produced in RStudio (version 1.2.5033).

Role of the funding source

The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.

Results

For the 168 nations included in this study, the global median PFP (determined with formula 3) was 15.0% (range 6.6-20.5), equating to 3.9 million (95% CI 2.5-5.6) premature deaths averted per year (figure, table).

The WHO region with the highest PFP was Africa (16.6% [12.1–20.5]; equating to 0.5 million deaths (95% CI 0.3–0.7) averted annually) and the region with the lowest prevented fraction was the Americas (13.1% [10.8–16.6]; 0.3 million deaths (95% CI 0.2–0.5) averted annually) closely followed by the Eastern Mediterranean region (13.2% [6.6–18.9]; 0.2 million deaths (95% CI 0.1–0.3); figure, table). The countries with the highest prevented fractions were Mozambique and Uganda (both

Joint region and income classification Africa High Upper-middle Lower-middle Lower-middle Eastern Mediterranean High Upper-middle Lower-middle	$\begin{array}{c} 17.3\%\\ 17.0\%\\ 17.5\%\\ 14.3\% (12.8-16.6)\\ 13.4\% (10.8-15.5)\\ 15.2\% (14.9-17.6)\\ 15.9\% (12.1-20.3)\\ 15.9\% (12.1-20.3)\\ 15.9\% (12.2-20.3)\\ 17.9\% (12.3-20.5)\\ 17.9\% (12.3-20.5)\\ 17.2\% (10.8-20.4)\\ 18.7\% (13.8-20.6)\\ 14.5\% (12.9-17.3)\\ 13.0\% (10.8-16.6)\\ 13.0\% (19.3-16.6)\\ 13.0\% (10.8-16.6.6)\\ 13.0\% (10.8-17.8)\\ 13.0\% (10.8-17.8)\\ 13.6\% (11.2-17.6)\\ 13.0\% (12.3-17.6)$	$\begin{array}{c} 0.1\\ 0.0\\ 0.1\\ 57.8\\ 19.9\\ 40.5\\ 182.1\\ 81.5\\ 100.9\\ 247.3\\ 113.0\\ 135.2\\ 184.7\\ 64.4\\ 126.9\\ 164.6\\ 61.8\\ 106.9\\ 7.5\\ 1.7\\ 6.0\\ 35.6\\ 16.0\\ 21.9\\ 132.1\\ 48.7\\ 86.3\\ 225.4\\ \end{array}$
Africa High Upper-middle Lower-middle Eastern Mediterranean High Upper-middle Lower-middle Europe High Upper-middle Lower-middle Lower-middle Lower-middle Lower-middle Lower-middle Lower-middle Lower-middle	$\begin{array}{c} 17.0\% \\ 17.5\% \\ 14.3\% (12.8-16.6) \\ 13.4\% (10.8-15.5) \\ 15.2\% (14.9-17.6) \\ 15.9\% (12.1-20.3) \\ 15.9\% (12.1-20.3) \\ 16.9\% (12.2-20.3) \\ 17.9\% (12.3-20.5) \\ 17.2\% (10.8-20.4) \\ 18.7\% (13.8-20.6) \\ 14.5\% (11.7-16.4) \\ 12.5\% (9.0-15.6) \\ 15.8\% (12.9-17.3) \\ 13.0\% (10.8-16.6) \\ 13.0\% (9.3-14.8) \\ 14.3\% (12.3-18.5) \\ 12.1\% (6.6-14.0) \\ 10.3\% (5.0-12.4) \\ 12.6\% (7.8-14.7) \\ 13.2\% (9.7-18.9) \\ 14.0\% (7.1-18.6) \\ 13.9\% (12.4-19.4) \\ 14.4\% (12.3-15.5) \\ 12.6\% (10.4-14.3) \\ 15.9\% (14.1-16.8) \\ 14.2\% (11.4-17.8) \\ 13.6\% (10.1-17.8) \end{array}$	$\begin{array}{c} 0.0\\ 0.1\\ 57.8\\ 19.9\\ 40.5\\ 182.1\\ 81.5\\ 100.9\\ 247.3\\ 113.0\\ 135.2\\ 113.0\\ 135.2\\ 184.7\\ 64.4\\ 126.9\\ 164.6\\ 61.8\\ 106.9\\ 7.5\\ 1.7\\ 6.0\\ 35.6\\ 16.0\\ 21.9\\ 132.1\\ 48.7\\ 86.3\\ \end{array}$
Upper-middle Lower-middle Low Americas High Upper-middle Eastern Mediterranean High Upper-middle Lower-middle Lower-middle Lower-middle Lower-middle Lower-middle Lower-middle Lower-middle Lower-middle Lower-middle Lower-middle Lower-middle Lower-middle Lower-middle Lower-middle Lower-middle	$\begin{array}{c} 17.0\% \\ 17.5\% \\ 14.3\% (12.8-16.6) \\ 13.4\% (10.8-15.5) \\ 15.2\% (14.9-17.6) \\ 15.9\% (12.1-20.3) \\ 15.9\% (12.1-20.3) \\ 16.9\% (12.2-20.3) \\ 17.9\% (12.3-20.5) \\ 17.2\% (10.8-20.4) \\ 18.7\% (13.8-20.6) \\ 14.5\% (11.7-16.4) \\ 12.5\% (9.0-15.6) \\ 15.8\% (12.9-17.3) \\ 13.0\% (10.8-16.6) \\ 13.0\% (9.3-14.8) \\ 14.3\% (12.3-18.5) \\ 12.1\% (6.6-14.0) \\ 10.3\% (5.0-12.4) \\ 12.6\% (7.8-14.7) \\ 13.2\% (9.7-18.9) \\ 14.0\% (7.1-18.6) \\ 13.9\% (12.4-19.4) \\ 14.4\% (12.3-15.5) \\ 12.6\% (10.4-14.3) \\ 15.9\% (14.1-16.8) \\ 14.2\% (11.4-17.8) \\ 13.6\% (10.1-17.8) \end{array}$	$\begin{array}{c} 0.0\\ 0.1\\ 57.8\\ 19.9\\ 40.5\\ 182.1\\ 81.5\\ 100.9\\ 247.3\\ 113.0\\ 135.2\\ 113.0\\ 135.2\\ 184.7\\ 64.4\\ 126.9\\ 164.6\\ 61.8\\ 106.9\\ 7.5\\ 1.7\\ 6.0\\ 35.6\\ 16.0\\ 21.9\\ 132.1\\ 48.7\\ 86.3\\ \end{array}$
Upper-middle Lower-middle Low Americas High Upper-middle Lower-middle	$\begin{array}{c} 17.5\% \\ 14.3\% (12.8-16.6) \\ 13.4\% (10.8-15.5) \\ 15.2\% (14.9-17.6) \\ 15.9\% (12.1-20.3) \\ 15.3\% (11.0-20.3) \\ 16.9\% (13.2-20.3) \\ 17.9\% (12.3-20.5) \\ 17.2\% (10.8-20.4) \\ 18.7\% (13.8-20.6) \\ 14.5\% (9.0-15.6) \\ 12.5\% (9.0-15.6) \\ 13.0\% (10.8-16.6) \\ 13.0\% (10.8-16.6) \\ 13.0\% (9.3-14.8) \\ 14.3\% (12.3-18.5) \\ 12.1\% (6.6-14.0) \\ 10.3\% (5.0-12.4) \\ 12.6\% (7.8-14.7) \\ 13.2\% (9.7-18.9) \\ 14.0\% (7.1-18.6) \\ 13.9\% (12.4-19.4) \\ 14.4\% (12.3-15.5) \\ 12.6\% (10.4-14.3) \\ 15.9\% (14.1-16.8) \\ 14.2\% (11.4-17.8) \\ 13.6\% (10.1-17.8) \\ \end{array}$	0.1 57.8 19.9 40.5 182.1 81.5 100.9 247.3 113.0 135.2 184.7 64.4 126.9 164.6 61.8 106.9 7.5 1.7 6.0 35.6 16.0 21.9 132.1 48.7 86.3
Lower-middle Low Americas High Upper-middle Eastern Mediterranean High Upper-middle Lower-middle Lower-middle Lower-middle Lower-middle Lower-middle Lower-middle	$\begin{array}{c} 14.3\% \left(12.8-16.6\right) \\ 13.4\% \left(10.8-15.5\right) \\ 15.2\% \left(14.9-17.6\right) \\ 15.9\% \left(12.1-20.3\right) \\ 15.9\% \left(12.2-20.3\right) \\ 16.9\% \left(13.2-20.3\right) \\ 17.9\% \left(12.3-20.5\right) \\ 17.2\% \left(10.8-20.4\right) \\ 18.7\% \left(13.8-20.6\right) \\ 14.5\% \left(11.7-16.4\right) \\ 12.5\% \left(9.0-15.6\right) \\ 15.8\% \left(12.9-17.3\right) \\ 13.0\% \left(10.8-16.6\right) \\ 13.0\% \left(9.3-14.8\right) \\ 14.3\% \left(12.3-18.5\right) \\ 12.1\% \left(6.6-14.0\right) \\ 10.3\% \left(5.0-12.4\right) \\ 12.6\% \left(7.8-14.7\right) \\ 13.2\% \left(9.7-18.9\right) \\ 14.0\% \left(7.1-18.6\right) \\ 13.9\% \left(12.3-15.5\right) \\ 12.6\% \left(10.4-14.3\right) \\ 15.9\% \left(14.1-16.8\right) \\ 14.2\% \left(11.4-17.8\right) \\ 13.6\% \left(10.1-17.8\right) \\ \end{array}$	$\begin{array}{c} 57.8\\ 19.9\\ 40.5\\ 182.1\\ 81.5\\ 100.9\\ 247.3\\ 113.0\\ 135.2\\ 184.7\\ 64.4\\ 126.9\\ 164.6\\ 61.8\\ 106.9\\ 7.5\\ 1.7\\ 6.0\\ 35.6\\ 16.0\\ 21.9\\ 132.1\\ 48.7\\ 86.3\\ \end{array}$
Lower-middle Low Americas High Upper-middle Eastern Mediterranean High Upper-middle Lower-middle Lower-middle Lower-middle Lower-middle Lower-middle Lower-middle	$\begin{array}{c} 13.4\% \left(10.8-15.5 \right) \\ 15.2\% \left(14.9-17.6 \right) \\ 15.9\% \left(12.1-20.3 \right) \\ 15.3\% \left(110-20.3 \right) \\ 16.9\% \left(13.2-20.3 \right) \\ 17.9\% \left(12.3-20.5 \right) \\ 17.2\% \left(10.8-20.4 \right) \\ 18.7\% \left(13.8-20.6 \right) \\ 14.5\% \left(11.7-16.4 \right) \\ 12.5\% \left(9.0-15.6 \right) \\ 15.8\% \left(12.9-17.3 \right) \\ 13.0\% \left(10.8-16.6 \right) \\ 13.0\% \left(9.3-14.8 \right) \\ 14.3\% \left(12.3-18.5 \right) \\ 12.1\% \left(6.6-14.0 \right) \\ 10.3\% \left(5.0-12.4 \right) \\ 12.6\% \left(7.8-14.7 \right) \\ 13.2\% \left(9.7-18.9 \right) \\ 14.0\% \left(7.1-18.6 \right) \\ 13.9\% \left(12.4-19.4 \right) \\ 14.4\% \left(12.3-15.5 \right) \\ 12.6\% \left(10.4-14.3 \right) \\ 15.9\% \left(14.1-16.8 \right) \\ 14.2\% \left(11.4-17.8 \right) \\ 13.6\% \left(10.1-17.8 \right) \\ \end{array}$	$\begin{array}{c} 19.9\\ 40.5\\ 182.1\\ 81.5\\ 100.9\\ 247.3\\ 113.0\\ 135.2\\ \end{array}$
Low Americas High Upper-middle Eastern Mediterranean High Upper-middle Lower-middle Lower-middle Lower-middle Lower-middle Lower-middle Low South-East Asia	$\begin{array}{c} 15.2\% \left(14.9-17.6\right) \\ 15.9\% \left(1220.3\right) \\ 15.3\% \left(11.0-20.3\right) \\ 16.9\% \left(12.3-20.5\right) \\ 17.9\% \left(12.3-20.5\right) \\ 17.9\% \left(10.8-20.4\right) \\ 18.7\% \left(13.8-20.6\right) \\ 14.5\% \left(11.7-16.4\right) \\ 12.5\% \left(9.0-15.6\right) \\ 15.8\% \left(12.9-17.3\right) \\ 13.0\% \left(10.8-16.6\right) \\ 13.0\% \left(9.3-14.8\right) \\ 14.3\% \left(12.3-18.5\right) \\ 12.1\% \left(6.6-14.0\right) \\ 10.3\% \left(5.0-12.4\right) \\ 12.6\% \left(7.8-14.7\right) \\ 13.2\% \left(9.7-18.9\right) \\ 14.0\% \left(7.1-18.6\right) \\ 13.9\% \left(12.4-19.4\right) \\ 14.4\% \left(12.3-15.5\right) \\ 12.6\% \left(10.4-14.3\right) \\ 15.9\% \left(14.1-16.8\right) \\ 14.2\% \left(11.4-17.8\right) \\ 13.6\% \left(10.1-17.8\right) \end{array}$	$\begin{array}{c} 40.5\\ 182.1\\ 81.5\\ 100.9\\ 247.3\\ 113.0\\ 135.2\\ \end{array}$
Low Americas High Upper-middle Eastern Mediterranean High Upper-middle Lower-middle Lower-middle Lower-middle Lower-middle Lower-middle Low South-East Asia	$\begin{array}{c} 15.9\% \left(12.1-20.3\right) \\ 15.3\% \left(11.0-20.3\right) \\ 16.9\% \left(13.2-20.3\right) \\ 17.9\% \left(12.3-20.5\right) \\ 17.2\% \left(10.8-20.4\right) \\ 18.7\% \left(13.8-20.6\right) \\ 14.5\% \left(11.7-16.4\right) \\ 12.5\% \left(9.0-15.6\right) \\ 15.8\% \left(12.9-17.3\right) \\ 13.0\% \left(10.8-16.6\right) \\ 13.0\% \left(9.3-14.8\right) \\ 14.3\% \left(12.3-18.5\right) \\ 12.1\% \left(6.6-14.0\right) \\ 10.3\% \left(5.0-12.4\right) \\ 12.6\% \left(7.8-14.7\right) \\ 13.2\% \left(9.7-18.9\right) \\ 14.0\% \left(7.1-18.6\right) \\ 13.9\% \left(12.4-19.4\right) \\ 14.4\% \left(12.3-15.5\right) \\ 12.6\% \left(10.4-14.3\right) \\ 15.9\% \left(14.1-16.8\right) \\ 14.2\% \left(11.4-17.8\right) \\ 13.6\% \left(10.1-17.8\right) \end{array}$	182.1 81.5 100.9 247.3 113.0 135.2 184.7 64.4 126.9 164.6 61.8 106.9 7.5 1.7 6.0 35.6 16.0 21.9 132.1 48.7 86.3
Americas High Upper-middle Eastern Mediterranean High Upper-middle Lower-middle Lower-middle Lower-middle Lower-middle Lower-middle Lower-middle Lower-middle	$\begin{array}{c} 15.3\% \left(11.0-20.3 \right) \\ 16.9\% \left(13.2-20.3 \right) \\ 17.9\% \left(12.3-20.5 \right) \\ 17.2\% \left(10.8-20.4 \right) \\ 18.7\% \left(13.8-20.6 \right) \\ 14.5\% \left(11.7-16.4 \right) \\ 12.5\% \left(9.0-15.6 \right) \\ 15.8\% \left(12.9-17.3 \right) \\ 13.0\% \left(10.8-16.6 \right) \\ 13.0\% \left(9.3-14.8 \right) \\ 14.3\% \left(12.3-18.5 \right) \\ 12.1\% \left(6.6-14.0 \right) \\ 10.3\% \left(5.0-12.4 \right) \\ 12.6\% \left(7.8-14.7 \right) \\ 13.2\% \left(9.7-18.9 \right) \\ 14.0\% \left(7.1-18.6 \right) \\ 13.9\% \left(12.4-19.4 \right) \\ 14.4\% \left(12.3-15.5 \right) \\ 12.6\% \left(10.4-14.3 \right) \\ 15.9\% \left(14.1-16.8 \right) \\ 14.2\% \left(11.4-17.8 \right) \\ 13.6\% \left(10.1-17.8 \right) \\ \end{array}$	$\begin{array}{c} 81.5\\ 100.9\\ 247.3\\ 113.0\\ 135.2\\ \end{array}\\ \begin{array}{c} 184.7\\ 64.4\\ 126.9\\ 164.6\\ 61.8\\ 106.9\\ \end{array}\\ \begin{array}{c} 7.5\\ 1.7\\ 6.0\\ 35.6\\ 16.0\\ 21.9\\ 132.1\\ 48.7\\ 86.3\\ \end{array}$
Americas High Upper-middle Eastern Mediterranean High Upper-middle Lower-middle Lower-middle Lower-middle Lower-middle Lower-middle Lower-middle Lower-middle	$\begin{array}{c} 17.9\% \left(12.3-20.5\right)\\ 17.2\% \left(10.8-20.4\right)\\ 18.7\% \left(13.8-20.6\right)\\ 14.5\% \left(11.7-16.4\right)\\ 12.5\% \left(9.0-15.6\right)\\ 15.8\% \left(12.9-17.3\right)\\ 13.0\% \left(10.8-16.6\right)\\ 13.0\% \left(9.3-14.8\right)\\ 14.3\% \left(12.3-18.5\right)\\ 12.1\% \left(6.6-14.0\right)\\ 10.3\% \left(5.0-12.4\right)\\ 12.6\% \left(7.8-14.7\right)\\ 13.2\% \left(9.7-18.9\right)\\ 14.0\% \left(7.1-18.6\right)\\ 13.9\% \left(12.4-19.4\right)\\ 14.4\% \left(12.3-15.5\right)\\ 12.6\% \left(10.4-14.3\right)\\ 15.9\% \left(14.1-16.8\right)\\ 14.2\% \left(11.4-17.8\right)\\ 13.6\% \left(10.1-17.8\right)\\ \end{array}$	247·3 113·0 135·2 184·7 64·4 126·9 164·6 61·8 106·9 7·5 1·7 6·0 35·6 16·0 21·9 132·1 48·7 86·3
Americas High Upper-middle Eastern Mediterranean High Upper-middle Lower-middle Lower-middle Lower-middle Lower-middle Lower-middle Lower-middle Lower-middle	$\begin{array}{c} 17.2\% \left(10.8-20.4 \right) \\ 18.7\% \left(13.8-20.6 \right) \\ 14.5\% \left(11.7-16.4 \right) \\ 12.5\% \left(9.0-15.6 \right) \\ 13.0\% \left(10.8-16.6 \right) \\ 13.0\% \left(9.3-14.8 \right) \\ 14.3\% \left(12.3-18.5 \right) \\ 12.1\% \left(6.6-14.0 \right) \\ 10.3\% \left(5.0-12.4 \right) \\ 12.6\% \left(7.8-14.7 \right) \\ 13.2\% \left(9.7-18.9 \right) \\ 14.0\% \left(7.1-18.6 \right) \\ 13.9\% \left(12.4-19.4 \right) \\ 14.4\% \left(122.3-15.5 \right) \\ 12.6\% \left(10.4-14.3 \right) \\ 15.9\% \left(14.1-16.8 \right) \\ 14.2\% \left(11.4-17.8 \right) \\ 13.6\% \left(10.1-17.8 \right) \\ 13.6\% \left(10.1-17.8 \right) \end{array}$	$113.0 \\ 135.2 \\ 184.7 \\ 64.4 \\ 126.9 \\ 164.6 \\ 61.8 \\ 106.9 \\ 7.5 \\ 1.7 \\ 6.0 \\ 35.6 \\ 16.0 \\ 21.9 \\ 132.1 \\ 48.7 \\ 86.3 \\ 86.3 \\ $
High Upper-middle Eastern Mediterranean High Upper-middle Lower-middle Lower-middle Lower-middle Lower-middle Lower-middle Lower-middle Lower-middle Lower-middle	18.7% (13.8-20.6) $14.5% (11.7-16.4)$ $12.5% (9.0-15.6)$ $13.0% (10.8-16.6)$ $13.0% (9.3-14.8)$ $14.3% (12.3-18.5)$ $12.1% (6.6-14.0)$ $10.3% (5.0-12.4)$ $12.6% (7.8-14.7)$ $13.2% (9.7-18.9)$ $14.0% (7.1-18.6)$ $13.9% (12.4-19.4)$ $14.4% (12.3-15.5)$ $12.6% (10.4-14.3)$ $15.9% (14.1-16.8)$ $14.2% (11.4-17.8)$ $13.6% (10.1-17.8)$	$135 \cdot 2$ $184 \cdot 7$ $64 \cdot 4$ $126 \cdot 9$ $164 \cdot 6$ $61 \cdot 8$ $106 \cdot 9$ $7 \cdot 5$ $1 \cdot 7$ $6 \cdot 0$ $35 \cdot 6$ $16 \cdot 0$ $21 \cdot 9$ $132 \cdot 1$ $48 \cdot 7$ $86 \cdot 3$
High Upper-middle Eastern Mediterranean High Upper-middle Lower-middle Lower-middle Lower-middle Lower-middle Lower-middle Lower-middle Lower-middle Lower-middle	$\begin{array}{c} 14.5\% \left(11.7-16.4\right)\\ 12.5\% \left(9.0-15.6\right)\\ 15.8\% \left(12.9-17.3\right)\\ 13.0\% \left(10.8-16.6\right)\\ 13.0\% \left(9.3-14.8\right)\\ 14.3\% \left(12.3-18.5\right)\\ \hline\\ 12.1\% \left(6.6-14.0\right)\\ 10.3\% \left(5.0-12.4\right)\\ 12.6\% \left(7.8-14.7\right)\\ 13.2\% \left(9.7-18.9\right)\\ 14.0\% \left(7.1-18.6\right)\\ 13.9\% \left(12.4-19.4\right)\\ 14.4\% \left(12.3-15.5\right)\\ 12.6\% \left(10.4-14.3\right)\\ 15.9\% \left(14.1-16.8\right)\\ \hline\\ 14.2\% \left(11.4-17.8\right)\\ 13.6\% \left(10.1-17.8\right)\\ \end{array}$	184.764.4126.9164.661.8106.97.51.76.035.616.021.9132.148.786.3
High Upper-middle Eastern Mediterranean High Upper-middle Lower-middle Lower-middle Lower-middle Lower-middle Lower-middle Lower-middle Lower-middle Lower-middle	12.5% (9.0-15.6) 15.8% (12.9-17.3) 13.0% (10.8-16.6) 13.0% (9.3-14.8) 14.3% (12.3-18.5) 12.1% (6.6-14.0) 10.3% (5.0-12.4) 12.6% (7.8-14.7) 13.2% (9.7-18.9) 14.0% (7.1-18.6) 13.9% (12.4-19.4) 14.4% (12.3-15.5) 12.6% (10.4-14.3) 15.9% (14.1-16.8) 14.2% (11.4-17.8) 13.6% (10.1-17.8) 13.6% (10.1-17.8) 13.6% (10.1-17.8) 13.6% (10.1-17.8) 13.6% (10.1-17.8) 13.6% (10.1-17.8) 13.6% (10.1-17.8) 13.6% (10.1-17.8) 13.6% (10.1-17.8) 13.6% (10.1-17.8) 13.6% (10.1-17.8) 13.6% (10.1-17.8) 13.6% (10.1-17.8) 13.6% (10.1-17.8) 13.6% (10.1-17.8) 13.6% (10.1-17.8) 13.0% (12.9-17.3) 13.0% (12.9-17.3) 13.0% (12.9-17.3) 13.0% (12.9-17.3) 14.0% (12.9-17.3) 15.0% (12.9-17.3)	64-4 126-9 164-6 61-8 106-9 7-5 1-7 6-0 35-6 16-0 21-9 132-1 48-7 86-3
Upper-middle Eastern Mediterranean High Upper-middle Lower-middle Lowe	12.5% (9.0-15.6) 15.8% (12.9-17.3) 13.0% (10.8-16.6) 13.0% (9.3-14.8) 14.3% (12.3-18.5) 12.1% (6.6-14.0) 10.3% (5.0-12.4) 12.6% (7.8-14.7) 13.2% (9.7-18.9) 14.0% (7.1-18.6) 13.9% (12.4-19.4) 14.4% (12.3-15.5) 12.6% (10.4-14.3) 15.9% (14.1-16.8) 14.2% (11.4-17.8) 13.6% (10.1-17.8) 13.6% (10.1-17.8) 13.6% (10.1-17.8) 13.6% (10.1-17.8) 13.6% (10.1-17.8) 13.6% (10.1-17.8) 13.6% (10.1-17.8) 13.6% (10.1-17.8) 13.6% (10.1-17.8) 13.6% (10.1-17.8) 13.6% (10.1-17.8) 13.6% (10.1-17.8) 13.6% (10.1-17.8) 13.6% (10.1-17.8) 13.6% (10.1-17.8) 13.6% (10.1-17.8) 13.0% (12.9-17.3) 13.0% (12.9-17.3) 13.0% (12.9-17.3) 13.0% (12.9-17.3) 14.0% (12.9-17.3) 15.0% (12.9-17.3)	64-4 126-9 164-6 61-8 106-9 7-5 1-7 6-0 35-6 16-0 21-9 132-1 48-7 86-3
Eastern Mediterranean High Upper-middle Lower-middle Lower-middle Lower-middle Lower-middle Lower-middle Lower-middle Lower-middle	$\begin{array}{c} 15.8\% \left(12.9{-}17{-}3\right) \\ 13.0\% \left(9{-}3{-}14{-}8\right) \\ 14.3\% \left(12{-}3{-}18{-}5\right) \\ \hline \\ 12.1\% \left(6{-}6{-}14{-}0\right) \\ 10.3\% \left(5{-}0{-}12{-}4\right) \\ 12.6\% \left(7{-}8{-}14{-}7\right) \\ 13.2\% \left(9{-}7{-}18{-}9\right) \\ 14.0\% \left(7{-}1{-}18{-}6\right) \\ 13.9\% \left(12{-}4{-}19{-}4\right) \\ 14{-}4\% \left(12{-}3{-}15{-}5\right) \\ 12.6\% \left(10{-}4{-}14{-}3\right) \\ 15.9\% \left(14{-}1{-}16{-}8\right) \\ \hline \\ 14.2\% \left(11{-}4{-}17{-}8\right) \\ 13.6\% \left(10{-}1{-}7{-}8\right) \\ \end{array}$	126-9 164-6 61-8 106-9 7-5 1-7 6-0 35-6 16-0 21-9 132-1 48-7 86-3
Eastern Mediterranean High Upper-middle Lower-middle Lower-middle Lower-middle Lower-middle Lower-middle Lower-middle Lower-middle	$\begin{array}{c} 13.0\% \left(10.8\text{-}16.6\right)\\ 13.0\% \left(9.3\text{-}14.8\right)\\ 14.3\% \left(12\text{-}3\text{-}18.5\right)\\ \hline\\ 12.1\% \left(6\text{-}6\text{-}14.0\right)\\ 10.3\% \left(5\text{-}0\text{-}12.4\right)\\ 12.6\% \left(7.8\text{-}14.7\right)\\ 13.2\% \left(9.7\text{-}18.9\right)\\ 14.0\% \left(7.1\text{-}18.6\right)\\ 13.9\% \left(12.4\text{-}19.4\right)\\ 14.4\% \left(12.3\text{-}15.5\right)\\ 12.6\% \left(10.4\text{-}14.3\right)\\ 15.9\% \left(14.1\text{-}16.8\right)\\ \hline\\ 14.2\% \left(11.4\text{-}17.8\right)\\ 13.6\% \left(10.1\text{-}17.8\right)\\ \end{array}$	164-6 61-8 106-9 7-5 1-7 6-0 35-6 16-0 21-9 132-1 48-7 86-3
Eastern Mediterranean High Upper-middle Lower-middle Lower-middle Lower-middle Lower-middle Lower-middle Lower-middle Lower-middle	$\begin{array}{c} 13.0\% \left(9.3-14.8 \right) \\ 14.3\% \left(12.3-18.5 \right) \\ \hline \\ 12.1\% \left(6.6-14.0 \right) \\ 10.3\% \left(5.0-12.4 \right) \\ 12.6\% \left(7.8-14.7 \right) \\ 13.2\% \left(9.7-18.9 \right) \\ 14.0\% \left(7.1-18.6 \right) \\ 13.9\% \left(12.4-19.4 \right) \\ 14.4\% \left(12.3-15.5 \right) \\ 12.6\% \left(10.4-14.3 \right) \\ 15.9\% \left(14.1-16.8 \right) \\ \hline \\ 14.2\% \left(11.4-17.8 \right) \\ 13.6\% \left(10.1-17.8 \right) \\ \end{array}$	61-8 106-9 7-5 1-7 6-0 35-6 16-0 21-9 132-1 48-7 86-3
High Upper-middle Lower-middle High Upper-middle Lower-middle Lower-middle Lower-middle Lower-middle Lower-middle Lower-middle	14.3% (12.3-18.5) $12.1% (6.6-14.0)$ $10.3% (5.0-12.4)$ $12.6% (7.8-14.7)$ $13.2% (9.7-18.9)$ $14.0% (7.1-18.6)$ $13.9% (12.4-19.4)$ $14.4% (12.3-15.5)$ $12.6% (10.4-14.3)$ $15.9% (14.1-16.8)$ $14.2% (11.4-17.8)$ $13.6% (10.1-17.8)$	106-9 7-5 1.7 6-0 35-6 16-0 21-9 132-1 48-7 86-3
High Upper-middle Lower-middle High Upper-middle Lower-middle Lower-middle Lower-middle Lower-middle Lower-middle	12.1% (6.6-14.0) 10.3% (5.0-12.4) 12.6% (7.8-14.7) 13.2% (9.7-18.9) 14.0% (7.1-18.6) 13.9% (12.4-19.4) 14.4% (12.3-15.5) 12.6% (10.4-14.3) 15.9% (14.1-16.8) 14.2% (11.4-17.8) 13.6% (10.1-17.8) 13.6% (10.1-17.8)	7.5 1.7 6.0 35.6 16.0 21.9 132.1 48.7 86.3
Upper-middle Lower-middle Lower-middle Lower-middle Lower-middle Lower-middle Lower-middle Lower-middle Low	$\begin{array}{c} 10.3\% \left(5.0{-}12.4\right) \\ 12.6\% \left(7.8{-}14.7\right) \\ 13.2\% \left(9.7{-}18.9\right) \\ 14.0\% \left(7.1{-}18.6\right) \\ 13.9\% \left(12.4{-}19.4\right) \\ 14.4\% \left(122.3{-}15.5\right) \\ 12.6\% \left(10.4{-}14.3\right) \\ 15.9\% \left(14.1{-}16.8\right) \\ \end{array}$	1.7 6.0 35.6 16.0 21.9 132.1 48.7 86.3
Upper-middle	$\begin{array}{c} 10.3\% \left(5.0{-}12.4\right) \\ 12.6\% \left(7.8{-}14.7\right) \\ 13.2\% \left(9.7{-}18.9\right) \\ 14.0\% \left(7.1{-}18.6\right) \\ 13.9\% \left(12.4{-}19.4\right) \\ 14.4\% \left(122.3{-}15.5\right) \\ 12.6\% \left(10.4{-}14.3\right) \\ 15.9\% \left(14.1{-}16.8\right) \\ \end{array}$	1.7 6.0 35.6 16.0 21.9 132.1 48.7 86.3
Lower-middle	$\begin{array}{c} 12.6\% \left(7.8-14.7\right)\\ 13.2\% \left(9.7-18.9\right)\\ 14.0\% \left(7.1-18.6\right)\\ 13.9\% \left(12.4-19.4\right)\\ 14.4\% \left(12.3-15.5\right)\\ 12.6\% \left(10.4-14.3\right)\\ 15.9\% \left(14.1-16.8\right)\\ \end{array}$	6.0 35.6 16.0 21.9 132.1 48.7 86.3
Lower-middle	$\begin{array}{c} 13.2\% \left(9.7-18.9\right)\\ 14.0\% \left(7.1-18.6\right)\\ 13.9\% \left(12.4-19.4\right)\\ 14.4\% \left(12.3-15.5\right)\\ 12.6\% \left(10.4-14.3\right)\\ 15.9\% \left(14.1-16.8\right)\\ \end{array}$	16·0 21·9 132·1 48·7 86·3
Europe High Upper-middle Lower-middle Low South-East Asia	13.9% (12.4-19.4) 14.4% (12.3-15.5) 12.6% (10.4-14.3) 15.9% (14.1-16.8) 14.2% (11.4-17.8) 13.6% (10.1-17.8)	21·9 132·1 48·7 86·3
Europe High Upper-middle Lower-middle Low South-East Asia	14.4% (12.3-15.5) 12.6% (10.4-14.3) 15.9% (14.1-16.8) 14.2% (11.4-17.8) 13.6% (10.1-17.8)	132·1 48·7 86·3
Europe High Upper-middle Lower-middle Low South-East Asia	12.6% (10.4–14.3) 15.9% (14.1–16.8) 14.2% (11.4–17.8) 13.6% (10.1–17.8)	48·7 86·3
High Upper-middle Lower-middle Low South-East Asia	15·9% (14·1–16·8) 14·2% (11·4–17·8) 13·6% (10·1–17·8)	86.3
High Upper-middle Lower-middle Low South-East Asia	14·2% (11·4–17·8) 13·6% (10·1–17·8)	
High Upper-middle Lower-middle Low South-East Asia	13.6% (10.1–17.8)	22F 4
Upper-middle Lower-middle Low South-East Asia	13.6% (10.1–17.8)	22E 4
Lower-middle		235.4
Lower-middle	15.0% (12.3–17.6)	79.5
Lower-middle		160.8
Low South-East Asia	15.2% (12.5-18.4)	288.0
Low South-East Asia	14·9% (11·5–18·3) 16·2% (13·3–18·5)	100·7 189·6
Low South-East Asia	17.5% (17.1–18.9)	93.8
South-East Asia	17.3% (15.9–19.1)	34.5
South-East Asia	18.6% (17.3–19.1)	60.1
	14.8%	2.8
	12.6%	0.9
	17.0%	2.0
Upper-middle		
···	15.2% (14.6–15.9)	47-2
▲ · · · · · · · · · · · · · · · · · · ·	14.4% (13.5–15.2)	17.2
	16.1% (15.6–16.5)	30.5
Lower-middle	16.3% (13.7–19.2)	1014.7
· · · · · · · · · · · · · · · · · · ·	14.8% (11.5-18.6)	366.7
	17.5% (15.9–19.8)	671.0
Low	18.6%	19·2
	18·2% 18·9%	8·3 11·0
Western pacific	10 5/0	11.0
High —	13.4% (11.8–17.5)	81.7
	12.8% (9.4–16.4)	25.1
	14.9% (12.5–18.5)	58.1
Upper-middle	16.3% (9.5-18.8)	1028.4
	14.1% (8.6–18.8)	435.9
· · · · · · · · · · · · · · · · · · ·	17.8% (10.3–19.8)	589.9
Lower-middle	17.6% (12.3–20.1)	107.3
	17.0% (10.4–20.4)	35.8
	18 80/ (10 1 00 7)	75·5
	18.8% (13.1–20.7)	
0 5 10 15 20	10.0% (13.1-20.7)	

Figure: Median PFP estimates and corresponding number of deaths averted

No range is presented for region and income groups with only one country. Countries in each region and income group are shown in the appendix (pp 29–36). Deaths averted is for the age range 40–74 years. Number of deaths averted for men and women might not add up to the estimate for both genders because the distributions of deaths across men and women are not even, and differences are magnified when multiplied by a derivative of activity prevalence, which also varies considerably by gender. PFP=prevented fraction for the population.

20.5% [95% CI 14.4-26.2]) and the country with the lowest prevented fraction was Kuwait (6.5% [4.0-9.6]; appendix pp 26–36). Similar results were observed for country-level data classified by gender, with women in

Niue and men in Tokelau also ranking among the populations with the highest prevented fractions (appendix pp 37–51). The median prevented fraction in countries classified as low income was higher than that in

													40-74 yea analysis)	40–74 years, thousands (Main analysis)	40–74 years, thousands (Main analysis)
	Main adjusted est counterfactual)*	Main adjusted estimate (0% activity counterfactual)*	6 activity	Unadjusted estim counterfactual)†	Unadjusted estimate (0% activity counterfactual)†	hctivity	Partially adjusted counterfactual)‡	Partially adjusted estimate (0% activity counterfactual)‡	(0% activity	Adjusted estimat counterfactual)§	Adjusted estimate (54.3% active counterfactual)§	6 active			
	Both genders	Women	Men	Both genders	Women	Men	Both genders	Women	Men	Both genders	Women	Men	Both genders	Women	Men
Overall	15·0% (6·6–20·5)	14·1% (5·0-20·4)	16·0% (7·8–20·7)	22.9% (10·5–30·2)	21.6% (8.1–30.1)	24·2% (12·4-30·5)	15.6% (7.2-20.6)	14.7% (5·5–20·6)	16-6% (8-4-20-8)	4·5% (0·3-10·5)	5.3% (0.2–12.1)	4·3% (0·0-9·6)	3929·9 (2480·3- 5602·4)	1511.7 (934·5- 2188·9)	2473-0 (1583-6- 3488-0)
WHO region Africa	16·6% (12·1-20·5)	15.8% (10.8–20.4)	17·5% (13·2-20·6)	25.0% (18.8–30·2)	24.0% (16.8–30·1)	26.4% (20.3-30.4)	17·1% (12·8–20·6)	16.4% (11.5-20.6)	18.0% (13.8–20.7)	6.1% (1.1–10-5)	6.9% (1.4-12.1)	6.0% (1.0–9.4)	487.2 (315.1- 680.7)	214·3 (138·2- 300·4)	276.7 (180.6– 385.0)
Americas	13·1% (10·8–16·6)	12.8% (9-0–15-6)	15.0% (12·3–18·5)	20·1% (16·9–25·1)	19·7% (14·2-23·7)	22·9% (19·0-27·7)	13.8% (11·6–17·1)	13.5% (9.7–16.2)	15.6% (13.0–18.9)	3·3% (0·3-6·2)	4.0% (0.2– 6.8)	3·2% (0·4-7·1)	349-3 (221-9- 498-2)	126·2 (79·1- 182·6)	233·8 (150·2- 329·8)
Eastern Mediterranean	13·2% (6·6–18·9)	12.0% (5.0–18.6)	14·1% (7·8–19·4)	20·4% (10·5–28·2)	18.7% (8.1–27.7)	21·6% (12·4-28·7)	13.9% (7.2-19.2)	12.8% (5.5–18.8)	14.7% (8.4–19.6)	3·1% (1·1-8·8)	3·3% (0·9- 10·0)	2·3% (0·1-8·0)	175·1 (106·9- 256·7)	66.4 (39.0- 99.8)	114·2 (72·1- 163·1)
Europe	14·6% (11·4-18·9)	13.8% (10.1–19.1)	15·5% (12·3–19·1)	22·3% (17·8–28·3)	21·1% (15·8-28·5)	23·6% (19·1–28·5)	15.2% (12·1–19·3)	14·4% (10·8–19·5)	16·1% (13·1-19·4)	3·9% (0·3-8·9)	4.7% (0.6–10.7)	3.6% (0.0-7.8)	619·9 (399·4- 873·5)	215.6 (137.8- 304.6)	412·4 (266·8– 576·7)
South-East Asia	16·1% (13·7–19·2)	15.0% (11.5–18.6)	17·2% (15·6–19·8)	24.4% (21.2–28.6)	22.9% (17.9-27.8)	25·9% (23·7–29·4)	16.7% (14.4–19.5)	15·6% (12·3–18·9)	17.7% (16.2–20.1)	5.6% (2.9–9.1)	6·1% (2·2-10·1)	5·6% (3·8–8·6)	1081·1 (655·8- 1586·2)	392·3 (223·4- 597·3)	712·5 (446·8- 1020·6)
Western Pacific	15·5% (9·5–20·1)	14·2% (8·6–20·4)	17·2% (10·3–20·7)	23.6% (14.9–29.8)	21.8% (13.6-30.1)	25·9% (16·2–30·5)	16·1% (10·2–20·3)	14·9% (9·2-20·5)	17.7% (11.1–20.8)	5·2% (0·5–10·1)	5.9% (0.7– 12.0)	5·9% (0·3-9·6)	1217·3 (781·2- 1707·2)	496·9 (316·9- 704·2)	723·5 (467·1- 1012·8)
World Bank income group classification High 14:1% 13:0 (6:6-17:8) (5:0	e group classific 14·1% (6·6-17·8)	ation 13.0% (5.0–17.8)	15-0% (7-8-18-5)	21.6% (10.5–26.7)	20-1% (8-1-26-9)	22·9% (12·4-27·7)	14.7% (7·2-18·2)	13.8% (5·5–18·4)	15.7% (8.4–18.9)	3.4% (0.3-7.5)	4.1% (0.6- 9.3)	3.1% (0.0-7.1)	509.3 (319.6– 733.0)	170.7 (105.5- 248.5)	351.7 (222.8- 500-9)
Upper-middle	14·0% (9·5–18·9)	13·1% (7·1–18·8)	15·1% (10·3–19·8)	21.5% (14·9–28·2)	20·3% (11·3-28·1)	23·1% (16·2–29·4)	14.7% (10.2–19.2)	13.8% (7·7–19·1)	15.8% (11:1–20·0)	3.8% (0.3-8.8)	4·4% (0·2– 10·3)	3.5% (0.1–8.6)	1621-5 (1046·2- 2269·0)	651-6 (417·7- 920·0)	979.4 (635.8- 1365.6)
Lower-middle	16·5% (12·1–20·3)	15.8% (10.4-20.4)	17·3% (13·1–20·7)	24·9% (18·8-29·9)	24.0% (16·3-30·1)	26-0% (20-2–30-5)	17.0% (12.8–20.5)	16·4% (11·1-20·5)	17-8% (13-8–20-8)	6.0% (1.1–10·3)	7.0% (0.9–12.0)	5·7% (0·9–9·6)	1529-9 (938-8- 2226-4)	567·2 (331·7- 850·7)	993.8 (627.9- 1416.6)
Low	17-9% (12-3-20-5)	17.2% (10.8–20.4)	18.7% (13.8–20.6)	26.9% (19.1–30.2)	25·9% (16·9–30·1)	27.8% (21·2–30·4)	18·3% (13·0–20·6)	17.7% (11·5–20·6)	19.0% (14·5-20·7)	7.7% (1.3–10.5)	8.5% (1·4-12·1)	7.3% (1.7–9.4)	269·3 (175·7- 374·0)	122·2 (79·5- 169·7)	148·2 (97·1- 204·9)

													40-74 yea analysis)	40–74 years, thousands (Main analysis)	s (Main
	Main adjusted esi counterfactual)*	Main adjusted estimate (0% activity counterfactual)*	6 activity	Unadjusted estin counterfactual)†	Unadjusted estimate (0% activity counterfactual)†	ctivity	Partially adjusted counterfactual)‡	Partially adjusted estimate (0% activity counterfactual)‡	(0% activity	Adjusted estimat counterfactual)§	Adjusted estimate (54.3% active counterfactual)§	% active			
	Both genders	Women	Men	Both genders	Women	Men	Both genders	Women	Men	Both genders	Women	Men	Both genders	Women	Men
(Continued from previous page)	revious page)														
WHO region and World Bank income group classification	'orld Bank incor	ne group classiì	fication												
Africa															
High	17.3%	17.0%	17.5%	26.0%	25.6%	26.4%	17.7%	17-5%	17.9%	%6.9	8.3%	5.9%	0.1 (0.1–0.1)	(0·0-0·0) 0·0	0.1 (0-0-0.1)
Upper-middle	14·3% (12·8–16·6)	13.4% (10.8–15.5)	15.2% (14:9-17.6)	21·9% (19·8–25·0)	20.7% (16.8–23·6)	23·2% (22·7–26·5)	14·9% (13·5-17·0)	14·1% (11·5–16·1)	15·9% (15·5–18·2)	3.6% (1.9–6.2)	4.3% (1.4-6.6)	3.4% (3.0–6.1)	57.8 (36.4- 82·9)	19-9 12-3- 29-2)	40·5 (26·2- 57·0)
Lower-middle	15·9% (12·1–20·3)	15·3% (11·0–20·3)	16.9% (13.2–20.3)	24·1% (18·8–29·9)	23·2% (17·2–30·0)	25.4% (20.3–29.9)	16·5% (12·8–20·5)	15·9% (11·7–20·5)	17.4% (13.8–20.4)	5.4% (1.1–10·3)	6.4% (1.7–12.0)	5.2% (1.0–9.1)	182·1 (117·3- 254·3)	81·5 (52·3- 114·4)	100·9 (65·7- 141·0)
Low	17·9% (12·3–20·5)	17.2% (10.8–20.4)	18.7% (13.8–20.6)	26.9% (19.1–30.2)	25·9% (16·9–30·1)	27.8% (21·2–30·4)	18.3% (13.0–20.6)	17.7% (11.5-20.6)	19.0% (14.5–20.7)	7·7% (1·3–10·5)	8.5% (1·4-12·1)	7·3% (1·7–9·4)	247·3 (161·3- 343·4)	113-0 (73-6- 156-9)	135·2 (88·6- 186·9)
Americas High	14·5% (11·7–16·4)	12·5% (9·0–15·6)	15.8% (12.9-17.3)	22·2% (18·1-24·8)	19.4% (14.2–23.7)	24-0% (20-0-26-0)	15.1% (12.4-17.0)	13.2% (9.7–16.2)	16·4% (13·6–17·7)	3.8% (0.6–6.0)	3.9% (1.1- 6.8)	4.0% (0.7–5.7)	184·7 (117·9- 262·9)	64.4 (40.4- 93·2)	126·9 (81·9- 178·4)
Upper-middle	13-0% (10-8-16-6)	13.0% (9-3–14-8)	14·3% (12·3–18·5)	20·1% (16·9–25·1)	20·1% (14·6–22·6)	22·0% (19·0–27·7)	13.7% (11.6–17.1)	13.7% (10.0–15.4)	15-0% (13-0–18-9)	2·2% (0·3-6·2)	4.0% (0.2– 5.8)	2.4% (0.4-7.1)	164·6 (104·0- 235·4)	61-8 (38-7- 89-4)	106·9 (68·3- 151·4)
Eastern Mediterranean High 12-1 (6-6	anean 12·1% (6·6–14·0)	10.3% (5·0-12·4)	12.6% (7.8–14·7)	18.7% (10.5–21.5)	16·2% (8·1-19·1)	19.5% (12.4-22.4)	12.8% (7.2–14.6)	11-0% (5·5–13·0)	13·3% (8·4-15·3)	2.2% (1.1-3.2)	1.0% (0.9–3.1)	1.8% (0·3–2·7)	7.5 (4.6-	1.7 (1·0-2·7)	6.0 (3·7–8·6)
Upper-middle	13.2% (9.7–18.9)	14.0% (7.1–18.6)	13.9% (12.4-19.4)	20·4% (15·3–28·2)	21.4% (11.3-27·7)	21·3% (19·3–28·7)	13·9% (10·5–19·2)	14·6% (7·7–18·8)	14·6% (13·1–19·6)	2.7% (2.3–8.8)	6·2% (2·8- 10·0)	1.8% (0.1–8.0)	35.6 (22.5- 50.9)	16.0 (10.3- 22.6)	21·9 (13·9- 31·1)
Lower-middle	14·4% (12·3–15·5)	12·6% (10·4-14·3)	15.9% (14.1–16.8)	22·1% (19·0-23·6)	19·6% (16·4-21·9)	24·1% (21·6–25·4)	15.0% (13.0–16.1)	13·4% (11·2-14·9)	16·5% (14·7–17·3)	3·7% (1·3–5·0)	3·5% (1·0–5·3)	4·1% (2·0–5·1)	132.1 132.1 (79.8– 194.8)	48.7 48.7 (27.7- 74.5)	86.3 86.3 (54.5- 123.3)
Europe High	14·2% (11·4-17·8)	13·6% (10·1-17·8)	15.0% (12:3-17·6)	21.7% (17.8–26.7)	20.8% (15.8–26·9)	22.9% (19.1–26.5)	14.8% (12.1-18.2)	14·3% (10·8-18·4)	15.7% (13.1–18.0)	3.4% (0.3-7.5)	4·5% (0·6–9·3)	3.1% (0.0-6.1)	235·4 (150·7- 333·3)	79.5 (50.5- 113.0)	160.8 (103.4- 225.9)

Matrix controllednessControlledness <th></th> <th>PFP, %</th> <th></th> <th>Deaths averted between ages 40-74 years, thousands (Main analysis)</th> <th>Deaths aver teu between ages 40–74 years, thousands (Main analysis)</th> <th>ts (Main</th>		PFP, %												Deaths averted between ages 40-74 years, thousands (Main analysis)	Deaths aver teu between ages 40–74 years, thousands (Main analysis)	ts (Main
Both Norme		Main adjuste counterfactu	ed estimate (0% al)*	6 activity	Unadjusted e counterfactu	stimate (0% a al)†	ctivity	Partially adju counterfactu	sted estimate al)‡	(0% activity	Adjusted es counterfact	timate (54·3% :ual)§	% active			
(oth model in provision page) 143% 157% 213% 214% 157% 213% 214% 213% 214% 213% 214% 213% 214% 213% 214% 213% 214% 213%		Both genders	Women	Men	Both genders	Women	Men	Both genders	Women	Men	Both genders	Women	Men	Both genders	Women	Men
Uppernidide 15.% 16.%	(Continued from	revious page)														
175% 175% <th< td=""><td>Upper-middl</td><td></td><td></td><td>16·2% (13·3–18·5)</td><td>23·2% (19·3–27·5)</td><td>22.8% (18.0–27·3)</td><td>24·5% (20·6–27·6)</td><td>15-8% (13-3–18-7)</td><td>15·6% (12·3-18·7)</td><td>16-7% (14-1–18-8)</td><td>4·6% (1·5-8·2)</td><td>6-0% (2-2-9-7)</td><td>4.4% (1.2-7.0)</td><td>288.0 (186.2- 404.8)</td><td>100·7 (64·5- 141·6)</td><td>189.6 (123.0- 263.9)</td></th<>	Upper-middl			16·2% (13·3–18·5)	23·2% (19·3–27·5)	22.8% (18.0–27·3)	24·5% (20·6–27·6)	15-8% (13-3–18-7)	15·6% (12·3-18·7)	16-7% (14-1–18-8)	4·6% (1·5-8·2)	6-0% (2-2-9-7)	4.4% (1.2-7.0)	288.0 (186.2- 404.8)	100·7 (64·5- 141·6)	189.6 (123.0- 263.9)
Iow 148% 126% 170% 226% 159% 154% 174% 24% 23% 24%	Lower-middle		17.3% (15.9–19.1)	18·6% (17·3-19·1)	26·2% (25·7–28·3)	26.0% (24.2–28.5)	27.7% (26.0–28.5)	17·9% (17·6–19·3)	17·8% (16·5–19·5)	18·9% (17·7–19·4)	7·1% (6·7–8·9)	8·6% (7·1-10·7)	7.1% (5.7–7.8)	93.8 (60.7- 131.3)	34·5 (22·2- 48·7)	60.1 (39.1- 84.1)
Dotementational 144% 161% 232% 213% 213% 154% 154% 46% 54% 54% 43% 47% 44% 47% 47% 47% 47% 44% 44% 47% 44% 47% 47% 44% 44% 47% 44% 44% 44% 44% 44% 44% 44% 44% 44% 44% 44%<	Low South East Asia		12.6%	17.0%	22.6%	19.6%	25.6%	15.4%	13.4%	17.5%	4.1%	3.4%	5.3%	2.8 (1.8-4.0)	0.9 (0.6–1.3)	2.0 (1·3-2·8)
Inverting 163% 148% 175% 246% 253% 563% 164% 179% 58% 58% 60% 1047 367 100 137-19.2 (115-186) (159-198) (179-278) (129-186) (137-186) (Upper-middle			16·1% (15·6–16·5)	23·2% (22·3-24·1)	22:1% (20:9–23:3)	24·3% (23·7–25·0)	15.8% (15.2–16.5)	15·1% (14·2–15·9)	16·6% (16·2–17·1)	4·6% (3·9–5·4)	5.4% (4.4–6.3)	4.3% (3.8-4.8)	47·2 (30·4- 66·2)	17·2 (11·0- 24·6)	30·5 (19·9- 43·0)
Low 18.6% 18.2% 18.9% 27.7% 27.3% 28.1% 18.6% 19.2% 8.4% 9.7% 7.5% 19.2 8.4 Western Pacific 13.4% 12.4% 14.9% 27.7% 19.9% 22.7% 14.4% 13.5% 15.5% 7.6% 7.5% 19.3 2.66 5.66 5.66% 15.5-17.90 10.01-16.90 13.2-18.90 0.3-7.10 14.65 13.5 15.5% 15.66 3.9% 15.66% 3.9% 15.66% 3.9% 15.66% 3.9% 15.66% 3.9% 15.66% 3.9% 15.66% 15.57% 15.55% 15.66% 15.57% 15.95% 15.66% 15.57% 15.95% 15.66% 15.75% 15.95% 15.66% 15.75% 15.95% 15.66% 15.279% 15.95% 15.25% 15.66% 15.27% 15.95% 15.27% 15.95% 15.27% 15.66% 15.27% 15.95% 15.27% 15.25% 15.25% 15.25% 15.25% 15.25% 15.25% 15.25% <t< td=""><td>Lower-middle</td><td></td><td>14·8% (11·5–18·6)</td><td>17·5% (15·9–19·8)</td><td>24·6% (21·2–28·6)</td><td>22·5% (17·9–27·8)</td><td>26·3% (24·1-29·4)</td><td>16-8% (14-4-19-5)</td><td>15·4% (12·3-18·9)</td><td>17-9% (16-5-20-1)</td><td>5.8% (2·9–9·1)</td><td>5.8% (2·2–10·1)</td><td>6.0% (4.1–8.6)</td><td>1014·7 (612·9- 1493·3)</td><td>366·7 (207·0- 561·2)</td><td>671.0 (419.7- 962·5)</td></t<>	Lower-middle		14·8% (11·5–18·6)	17·5% (15·9–19·8)	24·6% (21·2–28·6)	22·5% (17·9–27·8)	26·3% (24·1-29·4)	16-8% (14-4-19-5)	15·4% (12·3-18·9)	17-9% (16-5-20-1)	5.8% (2·9–9·1)	5.8% (2·2–10·1)	6.0% (4.1–8.6)	1014·7 (612·9- 1493·3)	366·7 (207·0- 561·2)	671.0 (419.7- 962·5)
Western Pacific Mestern Pa	Low	18.6%	18.2%	18·9%	27.7%	27.3%	28.1%	18.9%	18.6%	19.2%	8.4%	9.7%	7.5%	19.2 (12.6– 26.6)	8·3 (5·4-11·5)	11-0 (7·2-15·2)
Upper-middle 16.3% 14.1% 17.8% 24.6% 11.7% 26.6% 16.8% 14.8% 13.2% 7.0% 6.4% 6.4% 1028.4 435.9 (9.5-18.8) (10.3-19.8) (14.9-28.0) (13.6-2.29.4) (10.2-19.1) (92-19.1) (11.1-20.0) (05-8.6) (0.7-10.3) (0.8-8.6) (666.7- (280-9-1428) (10.3-19.8) (14.9-28.0) (13.6-2.81.1) (10.2-19.1) (11.1-20.0) (05-8.6) (0.7-10.3) (0.8-8.6) (666.7- (280-9-1428) (12.3-20.1) (12.3-20.1) (12.3-20.1) (12.3-20.2) (13.1-20.6) (13.7) (0.9-9.6) (68.7- (280-7) (225-5) (13.0-20.3) (11.1-20.6) (13.3-10.1) (0.9-9.6) (68.2- (225-6) (225-6) (21-3-10.1) (0.9-9.6) (68.2- (225-6) (225-6) (21-3-10.1) (12.3-20.2) (12.3-20.2) (11.1-20.6) (13.8-20.8) (13.8-20.6) (13.8-20.6) (13.8-20.6) (13.8-20.6) (13.8-20.6) (13.8-20.6) (13.8-20.6) (13.8-20.6) (13.8-20.6) (13.8-20.6) (13.8-20.6	Western Pacific High	13.4% (11.8-17.5)	12.8% (9.4–16.4)	14·9% (12·5-18·5)	20.7% (18·4-26·3)	19-9% (14-8-24-7)	22.7% (19.4-27.7)	14·1% (12·5-17·9)	13·5% (10·1–16·9)	15·5% (13·2–18·9)	2.6% (0.8-7.2)	3-9% (1-9- 7-6)	2.9% (0.3-7.1)	81.7 (46.3- 125.8)	25:1 (13.6– 39.7)	58·1 (33·7- 87·9)
Lower-middle17.6%17.0%18.8%26.5%25.6%27.9%18.1%17.4%19.1%7.3%8.2%7.4%107.335.8(12.3-20.1)(10.4-20.4)(13.1-20.7)(19.0-29.8)(16.3-30.1)(20.2-30.5)(13.0-20.3)(11.1-20.5)(13.8-20.8)(1.3-10.1)(0.9-12.0)(0.9-9.6)(68.2-(22.5-Data are median (range) or number (95% CIs). No range is presented for combined region and income groups with only one country. Countries in each region and income group are shown in the appendix (pp 29-36). Number of deaths are not even, and differences are magnified when multiplied by a derivative of activity prevalence, which a considerably by gender. PPP-prevented fraction for the population. RR=relative risk. 'The main estimates calculated with formula 3 (panel), the adjusted RR, and 0% activity counterfactual. The unadjusted estimates calculated with formula 2 (panel), the adjusted RR, and 0% activity counterfactual. The unadjusted estimates calculated with formula 2 (panel), the adjusted RR, and 0% activity counterfactual. The unadjusted estimates calculated with formula 2 (panel), the adjusted RR, and 0% activity counterfactual. The unadjusted estimates calculated with formula 2 (panel), the adjusted RR, and 0% activity counterfactual. The unadjusted estimates calculated with formula 2 (panel), the adjusted RR, and 0% activity counterfactual. The unadjusted estimates calculated with formula 2 (panel), the adjusted RR, and 0% activity counterfactual. The unadjusted estimates calculated with formula 2 (panel), the adjusted RR, and 0% activity counterfactual. The unadjusted estimates calculated using formula 2 (panel), the adjusted RR, and 0% activity counterfactual. The unadjusted estimates calculated with formula 2 (panel), the adjusted RR, and 0% activity counterfactual. The unadjusted estimates calc	Upper-middle		14·1% (8·6–18·8)	17.8% (10.3–19.8)	24·6% (14·9-28·0)	21.7% (13.6–28.1)	26·6% (16·2-29·4)	16-8% (10-2-19-1)	14·8% (9·2-19·1)	18·2% (11·1-20·0)	7.0% (0.5–8.6)	6.4% (0.7–10.3)	6.4% (0.8–8.6)	1028·4 (666·7- 1428·8)	435-9 (280-9- 612-7)	589·9 (384·6- 819·3)
Data are median (range) or number (95% CIs). No range is presented for combined region and income groups with only one country. Countries in each region and income group are shown in the appendix (pp 29-36). Number of deaths me and women and women might not add up to the estimate for both genders because the distributions of deaths across men and women are not even, and differences are magnified when multiplied by a derivative of activity prevalence, which a considerably by gender. PFP-prevented fraction for the population. RR-elative risk. "The main estimates calculated with formula 3 (panel), the adjusted RR, and 0% activity counterfactual. "The unadjusted estimates calculated with formula 2 (panel), the adjusted RR, and 0% activity counterfactual. "The unadjusted estimates calculated with formula 2 (panel), the adjusted RR, and 0% activity counterfactual. "The unadjusted estimates calculated with formula 2 (panel), the adjusted RR, and 0% activity counterfactual. "The partially adjusted estimates calculated using formula 2 (panel), the adjusted RR, and 0% activity counterfactual. "The partially adjusted estimates calculated using formula 2 (panel), the adjusted RR, and 54.3% counterfactual. Countries with a negative FP factivity prevalence <54.3%) were excluded.	Lower-middle		17.0% (10.4–20.4)	18.8% (13·1–20·7)	26·5% (19·0–29·8)	25·6% (16·3-30·1)	27.9% (20.2–30.5)	18·1% (13·0–20·3)	17·4% (11·1-20·5)	19-1% (13-8–20-8)	7·3% (1·3-10·1)	8.2% (0.9–12.0)	7·4% (0·9–9·6)	107·3 (68·2- 152·6)	35·8 (22·5- 51·9)	75·5 (48·8- 105·6)
	Data are median (rai men and women mi considerably by gen the unadjusted RR, and 54: adjusted RR, and 54:	ige) or number (9 ght not add up to ler. PFP=prevente nd 0% activity cou 3% active counter	15% Cls). No rang the estimate for d fraction for the unterfactual. ‡Th factual; countrie	je is presented fo • both genders be e population. RR= ne partially adjust is with a negative	r combined regic cause the distrib =relative risk. *Th ef estimates cal	n and income (utions of death le main estimat culated using fo evalence <54.3%	groups with only s across men an es calculated wi mmula 2 (panel), 6) were excluded	/ one country. Cc d women are no th formula 3 (pa , the adjusted Rf 1.	ountries in each t even, and diff mel), the adjust R, and 0% activi	region and incc erences are mag ed RR, and 0% a ty counterfactu	me group are inified when m ctivity counter al. §The adjust	shown in the a ultiplied by a d factual. †The u ed estimates co	ppendix (pp 29 lerivative of act madjusted estii alculated with f)–36). Numbe ivity prevalen mates calculai ormula 5 (app	er of deaths av cce, which also ted with form bendix pp 23-	rerted for o varies Iula 2 (pane 25), the

www.thelancet.com/lancetgh Vol 8 July 2020

lower-middle-income countries (17·9% [range $12 \cdot 3-20 \cdot 5$] νs 16·5% [12·1–20·3]; figure, table). In turn, lower-middle-income countries showed a higher prevented fraction than countries classified as upper-middle income (14·0% [9·5–18·9]) or high income (14·1% [6·6–17·8]). We identified a broad pattern of higher median prevented fractions for countries of lower income classifications within most regions, but the ranges overlapped.

The global median PFP was $14 \cdot 1\%$ ($5 \cdot 0-20 \cdot 4$) for women and $16 \cdot 0\%$ ($7 \cdot 8-20 \cdot 7$) for men (figure, table, appendix pp 37-51). The regional median prevented fraction values were between $1 \cdot 7$ and $3 \cdot 0$ percentage points lower for women, with the greatest difference in the Western Pacific region. The median prevented fraction values based on World Bank income classification were between $1 \cdot 5$ and $2 \cdot 0$ percentage points lower for women, with slightly greater differences between men and women in higher income countries than in lower income countries. We estimated that $1 \cdot 5$ million (95% CI $0 \cdot 9-2 \cdot 2$) annual deaths had been averted for women and $2 \cdot 5$ million ($1 \cdot 6-3 \cdot 5$) annual deaths for men by existing physical activity prevalence across all countries.

Sensitivity analyses with formula 2 produced higher estimates of the prevented fractions than our main analysis with formula 3. The global median prevented fraction with an unadjusted RR was 22.9% (range 10.5-30.2) and with an adjusted RR was 15.6% (7.2–20.6; table). In our third sensitivity analysis, we used a counterfactual of the median lowest observed prevalence of activity for each region, as opposed to 0% of the population meeting the physical activity guidelines (formula 5). The median lowest prevalence was 54.3%, which corresponded to a P_d of 44.7%. Countries that had a prevalence of activity lower than this counterfactual value were excluded (six countries overall; on gender-specific analyses, nine for women and four for men). In this analysis, global median prevented fraction was 4.5% (0.3-10.5%), which was 11.5 percentage points lower than our previous estimate (table). In all sensitivity analyses, the same patterns according to region, income classification, and gender were evident.

Discussion

Across 168 countries, the median percentage of premature mortality averted was $15 \cdot 0\%$, conservatively equating to $3 \cdot 9$ million deaths per year. We identified variations by WHO region and World Bank income classification: Africa had the highest median PFP, while the Americas and Eastern Mediterranean regions had the lowest. Countries with low-income classification tended to have higher prevented fractions than high-income countries. The prevented fractions were higher for men than for women, with similar patterns across regions and income classifications. To the best of our knowledge, these are the first national and global estimates of PFP associated with total physical activity. Furthermore, they are the first estimates derived from a formula that minimises bias from potential confounding in the disease–exposure relationship, and from the unequal distribution of activity across potential confounders. Use of PFP in this way has the potential to create a positive discourse around the existing efforts to promote physical activity.

Global differences in the prevented fractions reflect the differential prevalence of physical activity; estimations of averted deaths also factor in population size and mortality rates among people aged 40-75 years. The policy implications of the differences in activity prevalence have been discussed elsewhere.16 We view the implications of the present study to be similar across all nations and regions: a positive case can be made about existing amounts of physical activity, and we believe the results and the approach in general are powerful advocacy tools for policy makers and other stakeholders in public health. Use of PFP could support a positive position on physical activity that might be more conducive to political support than criticism of current policy, by showing the value of existing investment and services, particularly during economic hardship. We encourage the incorporation of these positive messages into the discourse and advocacy around physical activity policy at the global, regional, and country levels; for example, via scenario modelling to support the WHO Global Action Plan on Physical Activity¹ and the contribution of physical activity to the attainment of the Sustainable Development Goals.¹⁹

PFP is a complementary statistic to PAF, with each supporting a different approach to framing public health advocacy and messaging. PFP compares the current situation with the worst-case scenario, whereas PAF compares against the best-case scenario. Therefore, if activity prevalence increases, we would expect PFP to increase (representing increased benefits being accrued), and PAF to decrease (representing decreased potential for further gains). However, they are not directly comparable as proportions because they have different denominators: the number of deaths in a hypothetical worst-case scenario (PFP), and the number of deaths in the current situation (PAF). With that in mind, we compare our PFP estimate of 15.0% for physical activity with a PAF for physical inactivity, derived with similar methods by Ding and colleagues,⁴ of 6.4%. These statistics indicate that, although mortality burden could be reduced by 6.4% by increases in activity, if the prevalence of activity were to decrease to zero, mortality would be 15.0% higher.

Despite PAF being a standard epidemiological approach, one caveat, which also applies to PFP, is that the counterfactual is the most extreme scenario. Some researchers might argue that 0% or 100% of a population meeting the global physical activity recommendations is implausible; others might debate whether a minimum physical activity prevalence exists.²⁰ We therefore also estimated PFP using a minimum plausible activity prevalence of $54 \cdot 3\%$ as a counterfactual. The global median prevented fraction was $11 \cdot 5$ percentage points

lower than when a 0% activity prevalence counterfactual was used (4.5% vs 15.0%). Levine²¹ argued that PAF estimates are only meaningful if an intervention can be identified that could cause the assumed reduction in disease or mortality. The equivalent for PFP would be identifying the residual amount of activity that exists regardless of intervention.22 However, the burden that governments or individual initiatives claim to prevent becomes the quantity that they are responsible for maintaining, and so we believe these statistics have merit as an advocacy tool to start that discussion. Regarding the interpretation of these statistics, two further points should be considered. Firstly, changes in activity prevalence are unlikely to occur independent of other risk factors such as obesity, which causes difficulty in attributing any burden of mortality entirely to one risk factor.23 Secondly, reductions in premature mortality, despite being a good health indicator, do not necessarily translate to an extended healthy lifespan or a reduced overall burden on the health system.^{14,24}

Assumptions to note in the present study include our treatment of physical activity as a binary exposure, implying no benefits of undertaking a level of activity that is insufficient to meet the global recommendation. We know this not to be the case: the greatest reduction in mortality risk is evident with initial increases in activity at the low end of the activity level spectrum, and further benefits are associated with doing more than the minimum recommended amount.^{25,26} Therefore, we expect our estimates to be conservative. Our method is in line with previous work on the global burden of physical activity that used PAF estimates,^{4,17,27} but differs from the approach of Global Burden of Disease (GBD) studies, which used a multilevel categorisation of physical activity and the equivalent of our formula 2.67 These factors, along with the choices of prevalence and mortality data, and of RR values, make a considerable difference to estimates of PAF.67 For example, estimates from two different approaches gave a difference of 2 million deaths attributable to physical activity.⁶⁷ We expect similar variation with regard to PFP and estimated number of deaths averted. A 2020 study suggests that the magnitude of RR values for mortality associated with inactivity are increased when derived from accelerometermeasured behaviours.28 When global activity prevalence estimates are derived from standardised accelerometry protocols, the overall effect on estimates of PFP will be interesting to reassess.

We chose to be conservative by limiting data to deaths occurring between age 40–74 years. This age range matches that of many studies used to derive RR, and avoids counting causes of death that are not directly attributable to physical activity, such as neonatal complications or deaths among the oldest age groups that stretch the definition of avertable. We considered estimating the number of averted deaths in populations with non-communicable disease, but the available data were not provided for each country by age group. This avenue should be considered by future work if the data become available, although the events around coronavirus disease 2019 have brought into focus the role that physical activity might have in promoting immune function and preventing deaths from communicable disease.²⁹ The number of assumptions required, and the variability in estimates derived from different data sources led Lee and colleagues6 to question whether such differences make estimates of disease or mortality burden worthless. They concluded that their provision of a reference point still had substantial utility. We concur that these statistics are helpful indications of prevented, preventable, and attributable disease and mortality burdens; a way of translating the results of epidemiological or intervention studies into public health policy and practice. Some situations such as crosscountry comparisons will favour use of the prevented fraction, while others such as within-country advocacy might suit the use of the absolute number of deaths averted.

In conclusion, we estimated the median global burden of premature mortality averted by physical activity to be $15 \cdot 0\%$, conservatively equating to $3 \cdot 9$ million deaths annually. We propose use of PFP as a complimentary statistic to PAF in promoting healthy lifestyle behaviours, to make the cases of both what has been and of what could be achieved.

Contributors

TS and PK initially designed the study. All authors refined the study design and developed the concept. TS acquired and analysed the data, and drafted the manuscript with PK. All authors interpreted data and critically revised the manuscript. All authors have approved the final version for publication.

Declaration of interests

We declare no competing interests.

Data sharing

All data used in this study are publicly available and are referenced in the manuscript. The STATA code used to run the analyses is available on request.

Acknowledgments

TS, SB, and SJS are funded by the UK Medical Research Council (MRC; MC_UU_12015/1 and MC_UU_12015/3). DD is funded by a Future Leader Fellowship of the Australian Heart Foundation (number 101234). At the time of this work, MT was a member of the UK Centre for Diet and Activity Research, a UK Clinical Research Collaboration (UKCRC) Public Health Research Centre of Excellence funded by an MRC grant (MR/K023187/1). We gratefully acknowledge funding from the British Heart Foundation, Cancer Research UK, the Economic and Social Research Council, the MRC, the National Institute for Health Research, and the Wellcome Trust, under the auspices of the UKCRC. MT was also funded during his participation in the project "MEthods and Tools for Assessing the Health Impacts of Transport: modelling study" (MRC grant MR/P02663X/1).

Editorial note: the *Lancet* Group takes a neutral position with respect to territorial claims in published text and tables and institutional affiliations.

References

WHO. Global action plan on physical activity 2018–2030: more active people for a healthier world. Geneva: World Health Organization, 2018.

- 2 WHO, Food and Agriculture Organization of the United Nations. Driving commitment for nutrition within the UN decade of action on nutrition: policy brief (WHO/NMH/NHD/17.11). Geneva: World Health Organization, 2018.
- 3 WHO. Global status report on alcohol and health 2018. Geneva: World Health Organization, 2018.
- 4 Ding D, Lawson KD, Kolbe-Alexander TL, et al. The economic burden of physical inactivity: a global analysis of major non-communicable diseases. *Lancet* 2016; 388: 1311–24.
- 5 Aune D, Giovannucci E, Boffetta P, et al. Fruit and vegetable intake and the risk of cardiovascular disease, total cancer and all-cause mortality-a systematic review and dose-response meta-analysis of prospective studies. *Int J Epidemiol* 2017; 46: 1029–56.
- 6 Lee I-M, Bauman AE, Blair SN, et al. Annual deaths attributable to physical inactivity: whither the missing 2 million? *Lancet* 2013; 381: 992–93.
- 7 Lim SS, Carnahan E, Danaei G, et al. Annual deaths attributable to physical inactivity: whither the missing 2 million? – Authors' reply. *Lancet* 2013; **381**: 993.
- 8 Wen CP, Wu X. Stressing harms of physical inactivity to promote exercise. *Lancet* 2012; 380: 192–93.
- 9 Latimer AE, Brawley LR, Bassett RL. A systematic review of three approaches for constructing physical activity messages: what messages work and what improvements are needed? *Int J Behav Nutr Phys Act* 2010; 7: 36.
- 10 International Epidemiological Association. A dictionary of epidemiology, 6th edn. New York, NY: Oxford University Press, 2014.
- Benichou J. A review of adjusted estimators of attributable risk. Stat Methods Med Res 2001; 10: 195–216.
- 12 Miettinen OS. Proportion of disease caused or prevented by a given exposure, trait or intervention. *Am J Epidemiol* 1974; **99**: 325–32.
- Gail MH, Benichou J. Encyclopedia of epidemiologic methods. West Sussex: Wiley, 2000.
- 14 Greenland S. Concepts and pitfalls in measuring and interpreting attributable fractions, prevented fractions, and causation probabilities. *Ann Epidemiol* 2015; 25: 155–61.
- 15 WHO. Global recommendations on physical activity for health. Geneva: World Health Organization, 2010.
- 16 Guthold R, Stevens GA, Riley LM, Bull FC. Worldwide trends in insufficient physical activity from 2001 to 2016: a pooled analysis of 358 population-based surveys with 1.9 million participants. *Lancet Glob Health* 2018; 6: e1077–86.

- 17 Lee I-M, Shiroma EJ, Lobelo F, et al. Effect of physical inactivity on major non-communicable diseases worldwide: an analysis of burden of disease and life expectancy. *Lancet* 2012; 380: 219–29.
- 18 The World Bank. World Bank country and lending groups 2019. https://datahelpdesk.worldbank.org/knowledgebase/ articles/906519-world-bank-country-and-lending-groups (accessed May 12, 2020).
- 19 International Society for Physical Activity and Health. The Bangkok declaration on physical activity for global health and sustainable development. Br J Sports Med 2017; 51: 1389–91.
- 20 Brownson RC, Boehmer TK, Luke DA. Declining rates of physical activity in the United States: what are the contributors? Annu Rev Public Health 2005; 26: 421–43.
- 21 Levine B. What does the population attributable fraction mean? Prev Chronic Dis 2007; 4: A14.
- 22 Sallis JF, Owen N, Fisher EB. Ecological models of health behavior. In: Glanz K, Rimer BK, Viswanath K, eds. Health behavior and health education: theory, research and practice, 4th edn. San Francisco, CA: Jossey-Bass, 2008.
- 23 Mansournia MA, Altman DG. Population attributable fraction. BMJ 2018; 360: k757.
- 24 Mytton OT, Tainio M, Ogilvie D, Panter J, Cobiac L, Woodcock J. The modelled impact of increases in physical activity: the effect of both increased survival and reduced incidence of disease. *Eur J Epidemiol* 2017; 32: 235–50.
- 25 Physical Activity Guidelines Advisory Committee. 2018 Physical activity guidelines advisory committee scientific report. Washington, DC: US Department of Health and Human Services, 2018.
- 26 Blond K, Brinkløv CF, Ried-Larsen M, Crippa A, Grøntved A. Association of high amounts of physical activity with mortality risk: a systematic review and meta-analysis. Br J Sports Med 2019; published online Aug 12. DOI:10.1136/bjsports-2018-100393.
- 27 Sallis JF, Bull F, Guthold R, et al. Progress in physical activity over the Olympic quadrennium. *Lancet* 2016; 388: 1325–36.
- 28 Ekelund U, Dalene KE, Tarp J, Lee IM. Physical activity and mortality: what is the dose response and how big is the effect? Br J Sports Med 2020; published online Jan 21. DOI:10.1136/ bjsports-2019-101765.
- 29 Hamer M, O'Donovan G, Stamatakis E. Lifestyle risk factors, obesity and infectious disease mortality in the general population: linkage study of 97 844 adults from England and Scotland. *Prev Med* 2019; 123: 65–70.